The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | In vivo BCMA-targeted CAR T-cell therapy with LV169 in multiple myeloma
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses the early clinical development of LV169, an in vivo BCMA-targeted CAR T-cell therapy for relapsed/refractory multiple myeloma. She highlights the novel lentiviral platform, which generates CAR T cells directly in the patient, and discusses the ongoing Phase I clinical trial (NCT07802717) and early experience with this approach. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
At Mayo Clinic, we’re very excited to have recently opened the in vivo BCMA targeting CAR-T for patients with relapsed refractory multiple myeloma. Now, over the last year, we’ve seen some very exciting early data emerging from China and Australia with similar technologies for in vivo BCMA targeting CAR T. So this is a similar overall platform in terms of lentiviral-based way to generate CAR, but it’s modified so that it can be delivered directly as a drug infusion in the patient’s body, and the CAR T cells are generated in the body...
At Mayo Clinic, we’re very excited to have recently opened the in vivo BCMA targeting CAR-T for patients with relapsed refractory multiple myeloma. Now, over the last year, we’ve seen some very exciting early data emerging from China and Australia with similar technologies for in vivo BCMA targeting CAR T. So this is a similar overall platform in terms of lentiviral-based way to generate CAR, but it’s modified so that it can be delivered directly as a drug infusion in the patient’s body, and the CAR T cells are generated in the body. With this particular trial, with LV169, there are some differences in how the particles are engineered to avoid nonspecific uptake and try to direct the CAR vectors to the T cells. And the CAR construct is also a novel humanized CAR construct selected for specificity, including the potential ability to identify BCMA that may be mutated and to have T-cell specific expression of the CAR. So the clinical trial just started. We are enrolling in the dose expansion phase and welcome inquiries from providers or patients to see if they might potentially be eligible. And hopefully in the upcoming congress, we’ll present more of the clinical data.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
